Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521793 | 0.83 | CHRNB1 (0.45) | VNN1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3159343 | 0.73 | LTA4H (0.51) | CHRNB4CHRNA3 | |
| SCHEMBL13808895 | 0.72 | CHRNB1 (0.47) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL6224599 | 0.72 | CHRNB4 (0.43) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3147108 | 0.72 | CHRNB4 (0.43) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL31144917 | 0.71 | PLA2G2A (0.47) | — | |
| SCHEMBL12130332 | 0.71 | LTA4H (0.52) | AURKARPS6KB1KMT2A | |
| SCHEMBL5259527 | 0.70 | CHRNB1 (0.41) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL450027 | 0.69 | CHRNB4 (0.60) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL447049 | 0.69 | CHRNB4 (0.60) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2011-03-03 | — | — | US | claimed |
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | VNN1 4503/4885AURKA 53/4885RPS6KB1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.